Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$11.49 USD
-0.15 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.53 +0.04 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NTLA 11.49 -0.15(-1.29%)
Will NTLA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Other News for NTLA
NTLA Awards Inducement Grant Amid Employment Expansion
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA ...
Intellia Therapeutics announces employee inducement grants
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options